ストックスクリーナーアプリを入手
18.19
2.19%
0.39
アフターアワーズ：
18.19
前日終値:
$17.80
開ける：
$17.47
24時間の取引高:
219.54K
Relative Volume:
1.60
時価総額：
$974.92M
収益：
$2.22M
当期純損益:
$-40.51M
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
$-46.53M
1週間 パフォーマンス:
-28.55%
1か月 パフォーマンス:
-27.39%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$17.47
$18.41
1週間の範囲:
$17.09
$26.70
52週間の値動き範囲:
$17.09
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
UPB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| UPB | 18.19 | 974.92M | 2.22M | -40.51M | -46.53M | 0.00 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Upstream Bio Inc (UPB) 最新ニュース
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Upstream Bioprocessing Industry Analysis and Forecast, - GlobeNewswire
Upstream Bio, Inc.’s (NASDAQ:UPB) Quiet Period Set To End on November 20th - Defense World
Upstream Bio, Inc.'s (NASDAQ:UPB) Quiet Period Set To End on November 20th - MarketBeat
Brokers Set Expectations for Upstream Bio Q4 Earnings - MarketBeat
Upstream Bio Advances Clinical Trials, Strengthens Financials - TipRanks
Tezspire Phase III Nasal Polyp Data May Lead To Second Indication - Scrip
William Blair Weighs in on Upstream Bio Q4 Earnings - Defense World
Upstream Bio Inc (UPB) Quarterly 10-Q Report - Quartz
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
FMR LLC Acquires New Stake in Upstream Bio Inc - GuruFocus.com
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Upstream Bio initiated with an Overweight at Piper Sandler - MSN
Arrivent Biopharma Inc (AVBP-Q) QuotePress Release - The Globe and Mail
Here are Tuesday's biggest analyst calls: Apple, Microsoft, Palantir, Eli Lilly, Broadcom, Krispy Kreme, Live Nation & more - Head Topics
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
Upstream Bio initiated with an Overweight at JPMorgan - MSN
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Piper Sandler Begins Coverage on Upstream Bio (NASDAQ:UPB) - MarketBeat
TD Cowen bullish on Upstream Bio, bets on differentiated asthma treatment verekitug - Investing.com
Piper Sandler sees big potential for Upstream Bio asthma therapy, Overweight on stock - Investing.com UK
Upstream Bio prices IPO at $17 per share - MSN
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline News & Insights
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Goldman-backed drug developer Septerna raises $288 mln in US IPO - Reuters
Upstream Bio stock rallies 32% following upsized $255M IPO - MSN
Upstream Bioprocessing Market Forecast 2024: Key Global Developments - openPR
Upstream Bio Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Upstream Bio Rings the Opening Bell - Nasdaq
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com
OrbiMed Advisors LLC purchases $14 million in Upstream Bio shares - Investing.com India
Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc - Yahoo Finance
OrbiMed Advisors LLC purchases $14 million in Upstream Bio shares By Investing.com - Investing.com Nigeria
Upstream bio director Erez Chimovits buys $14 million in shares By Investing.com - Investing.com South Africa
Upstream bio director Erez Chimovits buys $14 million in shares - Investing.com
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
Chronic Rhinosinusitis with Nasal Polyps Market Expected - openPR
Upstream Bio and Camp4 and Ceribell Transactions - William Blair
Upstream Bio shares soar in impressive IPO - The Pharma Letter
Opening Day: Another trio of biotech IPOs make Friday debut - Yahoo Finance
HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering - Marketscreener.com
Upstream Bio Inc (UPB) 財務データ
収益
当期純利益
現金流量
EPS
Upstream Bio Inc (UPB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):